MetaCap

Lantheus (LNTH) vs Achieve Life Sciences (QUIT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lantheus is the larger company by market cap ($6.68 billion vs $573.2 million), about 11.6 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LNTH+1.18%QUIT-25.87%
+16%-6%-28%
Aug 17, 20261 yearNov 20, 2026
LNTH+2.13%QUIT-30.41%
+8%-12%-32%
Aug 17, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LNTH versus QUIT key metrics
MetricLNTHQUIT
Share price$102.10$5.56
Market cap$6.68B$573.25M
1-day change0.00%-5.28%
YTD return+53.42%—
1-year return+82.91%—
5-year return+266.08%—
P/E ratio (TTM)25.40—
Forward P/E15.34—
EPS (TTM)$4.02$-1.71
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.54B—
Revenue growth (YoY)+0.50%—
Net income (latest FY)$233.56M$-54.65M
Gross margin61.10%—
Operating margin20.16%—
Net margin15.15%—
52-week high$111.86$8.64
52-week low$54.94$2.62
Distance from 52-week high-8.73%-35.65%
Analyst consensusholdstrong_buy
Avg. price target upside+3.81%+162.23%
Average volume1.02M1.38M
Shares outstanding65.40M103.10M
Employees1,19328
SectorHealth CareHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesBiotechnology: In Vitro & In Vivo Diagnostic Substances

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Lantheus is about 11.6 times larger than Achieve Life Sciences by market value ($6.68B vs $573.25M).

About Lantheus

LNTH stock →

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 1,193 employees

About Achieve Life Sciences

QUIT stock →

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees

LNTH vs QUIT FAQ

Which is bigger, Lantheus or Achieve Life Sciences?

Lantheus (LNTH) is larger, with a market capitalization of $6.68B compared with $573.25M for Achieve Life Sciences (QUIT).

Are Lantheus and Achieve Life Sciences in the same industry?

Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.

More comparisons